Robust ribo.

Both MONALEESA-3 for post-menopausal women and MONALEESA-7 for pre-menopausal women demonstrated the holy grail of improved overall survival with the addition of the CDK 4/6 inhibitor ribociclib in addition to endocrine therapy for metastatic ER+ breast cancer. To complete the trifecta, we now have final reporting of the overall survival analysis of MONALEESA-2 where 664 post-menopausal women were randomized to +/- the addition of riboclib in addition to letrozole (as opposed to fulvestrant in M-3). In what can now be considered robust and reproducible findings, it reports a full year of additional life (median of 64 months versus 51 months) among the women receiving first-line ribociclib in addition to letrozole. | Hortobagyi, N Engl J Med 2022